{"id":"ropeginterferon","rwe":[],"tags":[],"safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Influenza-like illness","drugRate":"40%","severity":"common","organSystem":""},{"effect":"Arthralgia","drugRate":"40%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"40%","severity":"common","organSystem":""},{"effect":"Pruritus","drugRate":"40%","severity":"common","organSystem":""},{"effect":"Nasopharyngitis","drugRate":"40%","severity":"common","organSystem":""},{"effect":"Musculoskeletal pain","drugRate":"40%","severity":"common","organSystem":""},{"effect":"Liver enzyme elevations","drugRate":"20%","severity":"common","organSystem":""},{"effect":"Leukopenia","drugRate":"20%","severity":"common","organSystem":""},{"effect":"Thrombocytopenia","drugRate":"19%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"11%","severity":"common","organSystem":""}],"contraindications":["Autoimmune disease","Immunosuppressed transplant recipients","Moderate hepatic impairment","Severe depression","Severe hepatic impairment","Suicidal ideation","Suicide attempt"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[{"effect":"Urinary tract infection","drugRate":"8%","severity":"serious"},{"effect":"Transient ischemic attack","drugRate":"6%","severity":"serious"},{"effect":"Depression","drugRate":"4%","severity":"serious"}]},"trials":[],"_chembl":null,"aliases":["RoPegIFN"],"patents":[],"pricing":[],"offLabel":[],"timeline":[],"_dailymed":{"setId":"9583405d-53a0-49dc-88eb-5e6384ebabcb","title":"BESREMI (ROPEGINTERFERON ALFA-2B) INJECTION [PHARMAESSENTIA USA]"},"ecosystem":[],"mechanism":{"target":"Interferon alpha/beta receptor"},"_scrapedAt":"2026-03-27T23:37:21.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Polycythemia vera","diseaseId":"polycythemia-vera","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT07468916","phase":"PHASE2","title":"Ropeginterferon Alfa-2b for the Treatment of Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes and Chronic Myelomonocytic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2026-03-29","conditions":"Atypical Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm","enrollment":35},{"nctId":"NCT06743035","phase":"","title":"Ropeginterferon Alfa-2b in Patients With Polycythemia Vera (PV) Without Symptomatic Splenomegaly","status":"RECRUITING","sponsor":"iOMEDICO AG","startDate":"2024-12-03","conditions":"Polycythemia Vera","enrollment":200},{"nctId":"NCT07047885","phase":"PHASE1","title":"Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2025-08-27","conditions":"Cutaneous T Cell Lymphoma","enrollment":38},{"nctId":"NCT06752941","phase":"","title":"LOW-PV Continuation","status":"RECRUITING","sponsor":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","startDate":"2024-11-30","conditions":"Polycythemia Vera","enrollment":36},{"nctId":"NCT06506084","phase":"","title":"Observational Study on the Use of Ropeginterferon Alfa-2b in Polycythemia Vera (ROPEG-PV)","status":"ACTIVE_NOT_RECRUITING","sponsor":"FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS","startDate":"2022-09-08","conditions":"Polycythemia Vera","enrollment":319},{"nctId":"NCT07269470","phase":"PHASE2","title":"Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase","status":"NOT_YET_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2026-05-01","conditions":"Chronic Myeloid Leukemia","enrollment":40},{"nctId":"NCT07282132","phase":"","title":"Evaluation of Real-World Data on Ropeginterferon Alfa-2b in Patients With Polycythemia Vera: Insights From a Multicenter Study","status":"NOT_YET_RECRUITING","sponsor":"Federico II University","startDate":"2026-01-10","conditions":"Polycytemia Vera","enrollment":150},{"nctId":"NCT07249840","phase":"PHASE1","title":"Ropeginterferon for High Risk JAK2 Clonal Hematopoiesis","status":"NOT_YET_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-06","conditions":"JAK2 Mutation","enrollment":12},{"nctId":"NCT02370329","phase":"PHASE2","title":"P1101 in Treating Patients With Myelofibrosis","status":"TERMINATED","sponsor":"Mayo Clinic","startDate":"2015-08-12","conditions":"Primary Myelofibrosis, Secondary Myelofibrosis","enrollment":11},{"nctId":"NCT04182100","phase":"PHASE2","title":"Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply","status":"COMPLETED","sponsor":"PharmaEssentia Japan K.K.","startDate":"2019-12-20","conditions":"Polycythemia Vera (PV)","enrollment":29},{"nctId":"NCT07105319","phase":"PHASE4","title":"Ropeginterferon for Treatment Free Remission","status":"COMPLETED","sponsor":"Dong-Wook Kim","startDate":"2021-11-30","conditions":"CML (Chronic Myelogenous Leukemia)","enrollment":65},{"nctId":"NCT04285086","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2020-08-25","conditions":"Essential Thrombocythemia","enrollment":174},{"nctId":"NCT05481151","phase":"PHASE3","title":"A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2022-10-26","conditions":"Polycythemia Vera","enrollment":111},{"nctId":"NCT06468033","phase":"PHASE3","title":"P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk","status":"RECRUITING","sponsor":"PharmaEssentia","startDate":"2025-07-18","conditions":"Primary Myelofibrosis, Myeloproliferative Neoplasm","enrollment":150},{"nctId":"NCT05482971","phase":"PHASE2","title":"A Single-arm, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of P1101 in Adults With ET","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2022-09-29","conditions":"Essential Thrombocythemia","enrollment":91},{"nctId":"NCT05485948","phase":"PHASE2","title":"A Study to Access Efficacy and Safety of P1101 in Chinese PV Patients Who Are Intolerant or Resistance to HU","status":"ACTIVE_NOT_RECRUITING","sponsor":"PharmaEssentia","startDate":"2021-10-08","conditions":"Polycythemia Vera","enrollment":49},{"nctId":"NCT06290765","phase":"PHASE4","title":"Efficacy and Safety of Ropeginterferon Alfa 2b (P1101) for Patients With Polycythemia Vera","status":"NOT_YET_RECRUITING","sponsor":"PharmaEssentia","startDate":"2026-02-01","conditions":"Polycythemia Vera, Myeloproliferative Neoplasm","enrollment":70},{"nctId":"NCT07053904","phase":"PHASE1","title":"Phase I Open-Label Study of P1101 Followed by P1801 in Advanced Solid Tumors","status":"ENROLLING_BY_INVITATION","sponsor":"PharmaEssentia","startDate":"2025-04-21","conditions":"Advanced Solid Tumors","enrollment":54},{"nctId":"NCT04638439","phase":"PHASE1","title":"The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2022-08-17","conditions":"Chronic Hepatitis B Infection, Chronic Hepatitis D Infection","enrollment":20},{"nctId":"NCT06770842","phase":"PHASE2","title":"Ropeginterferon Alfa 2b Plus Ruxolitinib for Myelofibrosis","status":"RECRUITING","sponsor":"The University of Hong Kong","startDate":"2025-03-01","conditions":"Primary Myelofibrosis (PMF), Post Polycythemia Myelofibrosis (PPV MF), Post Essential Thrombocythaemia Myelofibrosis (PET-MF)","enrollment":20},{"nctId":"NCT03831776","phase":"PHASE2","title":"Long-acting Low Dose Ropeginterferon for Chronic Myeloid Leukemia Treated With Bosutinib From Diagnosis","status":"COMPLETED","sponsor":"St. Olavs Hospital","startDate":"2019-03-25","conditions":"Chronic Myeloid Leukemia","enrollment":212},{"nctId":"NCT06514807","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"AOP Orphan Pharmaceuticals AG","startDate":"2023-12-04","conditions":"Essential Thrombocythaemia","enrollment":117},{"nctId":"NCT06002490","phase":"PHASE3","title":"A Study to Evaluate P1101 in Japanese PV Patients","status":"COMPLETED","sponsor":"PharmaEssentia Japan K.K.","startDate":"2023-10-17","conditions":"Polycythemia Vera (PV)","enrollment":21},{"nctId":"NCT04655092","phase":"PHASE3","title":"Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients","status":"RECRUITING","sponsor":"PharmaEssentia Japan K.K.","startDate":"2021-01-19","conditions":"Polycythemia Vera (PV)","enrollment":67},{"nctId":"NCT05770466","phase":"PHASE3","title":"Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Moderate COVID19.","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2022-04-01","conditions":"COVID-19","enrollment":134},{"nctId":"NCT05808322","phase":"PHASE2, PHASE3","title":"Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-05-15","conditions":"COVID-19","enrollment":60},{"nctId":"NCT05731245","phase":"PHASE2","title":"Ropeginterferon Alfa 2b for Early MyelofibrosisDIPSS Low/Intermediate-1 Risk Myelofibrosis","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2023-02-08","conditions":"Pre-fibrotic Myelofibrosis","enrollment":50},{"nctId":"NCT05467553","phase":"PHASE2","title":"A Study to Compare P1101 Plus TAF With or Without UDCA in Patients With HBV and HDV Co-Infection","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2023-02-24","conditions":"Hepatitis D","enrollment":30},{"nctId":"NCT05494528","phase":"NA","title":"Comparing P1101 to Entecavir in Patients With HBeAg(-) Hepatitis B Under Long-term Nucleos(t)Ide Analogue Therapy","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2021-05-04","conditions":"Chronic Hepatitis B Virus Infection","enrollment":90},{"nctId":"NCT04988815","phase":"PHASE2","title":"Ropeginterferon Alfa 2b for Early Myelofibrosis","status":"UNKNOWN","sponsor":"The University of Hong Kong","startDate":"2021-09-01","conditions":"Primary Myelofibrosis, Prefibrotic Stage, Myelofibrosis","enrollment":50},{"nctId":"NCT04774107","phase":"PHASE1","title":"The Pharmacokinetics of P1101 + Ribavirin in Interferon Treatment-Naïve Subjects With Chronic Hepatitis C Virus (HCV) Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2020-11-26","conditions":"Hepatitis C, Chronic","enrollment":17},{"nctId":"NCT04233840","phase":"PHASE1, PHASE2","title":"P1101 and Anti-PD1 for After Curative Surgery of Hepatitis B-related Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2019-02-12","conditions":"Hepatocellular Carcinoma","enrollment":72},{"nctId":"NCT04382937","phase":"PHASE3","title":"Ropeginterferon Alfa-2b (P1101) Phase 3 Study in Interferon Treatment-Naive Subjects With HCV Genotype 2 Infection","status":"COMPLETED","sponsor":"PharmaEssentia","startDate":"2016-01-12","conditions":"Chronic Hepatitis C Virus Infection","enrollment":222},{"nctId":"NCT03546465","phase":"PHASE1","title":"Safety, Tolerability, Pharmacokinetics & Pharmacodynamics Study of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects","status":"COMPLETED","sponsor":"PharmaEssentia Japan K.K.","startDate":"2018-05-07","conditions":"Healthy Volunteers","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":8,"reaction":"OFF LABEL USE"},{"count":6,"reaction":"FATIGUE"},{"count":4,"reaction":"ARTHRALGIA"},{"count":4,"reaction":"HAEMATOCRIT INCREASED"},{"count":4,"reaction":"PRURITUS"},{"count":3,"reaction":"DIARRHOEA"},{"count":3,"reaction":"INSOMNIA"},{"count":3,"reaction":"PAIN"},{"count":3,"reaction":"PLATELET COUNT INCREASED"},{"count":2,"reaction":"ABDOMINAL DISCOMFORT"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Other"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturerList":[],"phase":"marketed","status":"active","brandName":"Ropeginterferon","genericName":"Ropeginterferon","companyName":"St. Olavs Hospital","companyId":"st-olavs-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":4,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}